Intracavernosal Platelet Rich Plasma with Phosphodiesterase Type 5 Inhibitors Versus Phosphodiesterase Type 5 Inhibitors in Management of Erectile Dysfunction: A comparative randomized study
Desoki, A., Alam-Eldin, A., Gad, H., Hanna, P., Amira, H., hussein, M. (2024). Intracavernosal Platelet Rich Plasma with Phosphodiesterase Type 5 Inhibitors Versus Phosphodiesterase Type 5 Inhibitors in Management of Erectile Dysfunction: A comparative randomized study. EKB Journal Management System, 4(1), 34-45. doi: 10.21608/aumj.2024.258767.1097
Ahmed Mohamed Desoki; Amr Alam-Eldin; Hassaan Ali Gad; Peter Hanna; Hisham abdelbarr Amira; Mohamed mostafa hussein. "Intracavernosal Platelet Rich Plasma with Phosphodiesterase Type 5 Inhibitors Versus Phosphodiesterase Type 5 Inhibitors in Management of Erectile Dysfunction: A comparative randomized study". EKB Journal Management System, 4, 1, 2024, 34-45. doi: 10.21608/aumj.2024.258767.1097
Desoki, A., Alam-Eldin, A., Gad, H., Hanna, P., Amira, H., hussein, M. (2024). 'Intracavernosal Platelet Rich Plasma with Phosphodiesterase Type 5 Inhibitors Versus Phosphodiesterase Type 5 Inhibitors in Management of Erectile Dysfunction: A comparative randomized study', EKB Journal Management System, 4(1), pp. 34-45. doi: 10.21608/aumj.2024.258767.1097
Desoki, A., Alam-Eldin, A., Gad, H., Hanna, P., Amira, H., hussein, M. Intracavernosal Platelet Rich Plasma with Phosphodiesterase Type 5 Inhibitors Versus Phosphodiesterase Type 5 Inhibitors in Management of Erectile Dysfunction: A comparative randomized study. EKB Journal Management System, 2024; 4(1): 34-45. doi: 10.21608/aumj.2024.258767.1097

Intracavernosal Platelet Rich Plasma with Phosphodiesterase Type 5 Inhibitors Versus Phosphodiesterase Type 5 Inhibitors in Management of Erectile Dysfunction: A comparative randomized study

Aswan University Medical Journal
Article 4, Volume 4, Issue 1, June 2024, Pages 34-45    PDF (620.4 K)
Document Type: Original Article
DOI: 10.21608/aumj.2024.258767.1097
Authors
Ahmed Mohamed Desoki* ; Amr Alam-Eldin; Hassaan Ali Gad; Peter Hanna; Hisham abdelbarr Amira; Mohamed mostafa hussein
Urology department , Faculty of Medicine, Aswan University
Abstract
Background: Erectile Dysfunction (ED) is defined as inability to achieve and/or maintain an erection sufficient for satisfactory sexual performance. Objective: To assess the use of intracavernosal injection of platelet rich plasma (PRP) with and without oral Phosphodiesterase type 5 inhibitors for treatment of ED. Methods: A prospective randomized study included 38 Patients. They were randomly allocated in two groups, 19 each. The two group was treated by daily Phosphodiesterase type 5 inhibitors (tadalafil 5 mg). Group A had intracavernosal injection of PRP, while group B had saline 0.9% (placebo). All patients answered the Arabic version of IIEF-5 questionnaire in structured interview before and 3 months after initiation of therapy. Results: The mean ILEF-5 score in group A was 9.84 before which increased to 17.6 after injection (p-value> 0.001), Meanwhile, the mean ILEF-5 score in group B before injection was 9.89 and after injection was 12.9 (p-value > 0.001). Furthermore, the mean difference for (ILEF-5) score between both groups after injection was 4.68 (p-value > 0.014). Conclusion: ICI of PRP with PDE5 inhibitors improves erectile function and patient satisfaction more than PDE5 inhibitors alone and might be an optional treatment for patients with erectile dysfunction.
Keywords
Erectile dysfunction; platelet rich plasma; Phosphodiesterase type 5 inhibitors
Statistics
Article View: 232
PDF Download: 207